Design Therapeutics Inc. (NASDAQ:DSGN)’s traded shares stood at 3.83 million during the last session. At the close of trading, the stock’s price was $6.48, to imply a decrease of -7.82% or -$0.55 in intraday trading. The DSGN share’s 52-week high remains $26.30, putting it -305.86% down since that peak but still an impressive 6.17% since price per share fell to its 52-week low of $6.08. The company has a valuation of $374.61M, with an average of 0.85 million shares in intraday trading volume over the past 10 days and average of 438.01K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Design Therapeutics Inc. (DSGN), translating to a mean rating of 2.00. Of 5 analyst(s) looking at the stock, 1 analyst(s) give DSGN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.34.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Design Therapeutics Inc. (NASDAQ:DSGN) trade information
After registering a -7.82% downside in the last session, Design Therapeutics Inc. (DSGN) has traded red over the past five days. The stock hit a weekly high of 7.58 this Friday, 03/17/23, dropping -7.82% in its intraday price action. The 5-day price performance for the stock is -0.15%, and -5.68% over 30 days. With these gigs, the year-to-date price performance is -36.84%. Short interest in Design Therapeutics Inc. (NASDAQ:DSGN) saw shorts transact 7.26 million shares and set a 16.37 days time to cover.
Analysts on Wall Street suggest a consensus price target of $22.80, implying an increase of 71.58% to the stock’s current value. The extremes give us $6.00 and $42.00 for target low and target high price respectively. As such, DSGN has been trading -548.15% off suggested target high and 7.41% from its likely low.
Design Therapeutics Inc. (DSGN) estimates and forecasts
Looking at statistics comparing Design Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Design Therapeutics Inc. (DSGN) shares are -71.49% down over the last 6 months, with its year-to-date growth rate lower than industry average at -43.86% against 9.60%. Revenue is forecast to shrink -70.00% this quarter before falling -54.20% for the next one.
Design Therapeutics Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Design Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Design Therapeutics Inc. (NASDAQ:DSGN)’s Major holders
Design Therapeutics Inc. insiders hold 36.73% of total outstanding shares, with institutional holders owning 78.73% of the shares at 124.43% float percentage. In total, 78.73% institutions holds shares in the company, led by SR One Capital Management, LP. As of Dec 30, 2022, the company held over 6.53 million shares (or 11.67% of shares), all amounting to roughly $66.96 million.
The next major institution holding the largest number of shares is Cormorant Asset Management, LP with 5.0 million shares, or about 8.94% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $83.6 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Design Therapeutics Inc. (DSGN) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 2.33 million shares. This is just over 4.17% of the total shares, with a market valuation of $23.92 million. Data from the same date shows that the other fund manager holds a little less at 0.81 million, or 1.44% of the shares, all valued at about 11.29 million.